Welcome to our dedicated page for Elutia news (Ticker: ELUT), a resource for investors and traders seeking the latest updates and insights on Elutia stock.
Elutia Inc. develops and commercializes drug-eluting biomatrix products designed to improve compatibility between implanted medical devices and patients. Company news commonly covers financial results, product revenue from SimpliDerm and cardiovascular products, and development updates for NXT-41 and NXT-41x biomatrix technologies used in surgical reconstruction and related applications.
Recurring updates also include regulatory-process disclosures, commercial planning for plastic and reconstructive surgery, management presentations, equity compensation actions, and Nasdaq listing-compliance matters for Elutia's Class A common stock. The company's communications often connect its biomatrix platform with implant-based breast reconstruction, post-surgical infection reduction, and broader surgical-support use cases.
Elutia (Nasdaq: ELUT) has published significant clinical and preclinical data demonstrating the effectiveness of their biologic envelopes for cardiac implantable electronic devices (CIEDs). The HEAL study revealed that patients with ECM envelopes experienced 43% lower overall procedural difficulty, including 46% easier generator mobilization and 41% easier lead mobilization during reoperations.
The research also showed complete eradication of bacterial pathogens, including MRSA, with sustained local antibiotic concentrations for up to two weeks. The company's drug-eluting biomatrix technology combines regenerative ECM with broad-spectrum antibiotics to address both infection control and tissue remodeling, with potential applications in higher-risk procedures like breast reconstruction.
Elutia (Nasdaq: ELUT) has announced the sale of its BioEnvelope business, including EluPro™ and CanGaroo® bioenvelopes, to Boston Scientific Corporation (NYSE: BSX) for $88 million in cash. The transaction is expected to close in Q4 2025.
The deal represents a strategic move that validates Elutia's drug-eluting biologics platform and provides non-dilutive funding for the development of NXT-41, targeting the $1.5 billion U.S. breast reconstruction market. The proceeds will enable Elutia to eliminate outstanding debt, address litigation from its previous Orthobiologics business, and reduce burn rate while focusing on advancing its SimpliDerm franchise.
Elutia (Nasdaq: ELUT) has been selected to showcase its EluPro™ Antibiotic-Eluting BioEnvelope at the Vizient Innovative Technology Exchange on September 17, 2025, in Las Vegas. EluPro is the first and only FDA-cleared antibiotic-eluting bioenvelope designed for cardiac implantable electronic devices and neurostimulators.
The technology combines a natural biologic scaffold with time-release antibiotics to promote tissue regeneration while providing antimicrobial protection at the surgical site. The product aims to address post-surgical complications including infection, migration, and erosion while enhancing procedural efficiency.
Elutia (Nasdaq: ELUT), a drug-eluting biomatrix technologies company, has announced its participation in three upcoming investor conferences in New York this September.
The company's leadership, including CEO Dr. Randy Mills and CFO Matt Ferguson, will attend the Cantor Global Healthcare Conference (Sept. 4), the H.C. Wainwright Global Investment Conference (Sept. 10), and the Lake Street Capital Markets Best Ideas Growth Conference (Sept. 11). The first two events will feature fireside chats and presentations, while the Lake Street conference will focus on one-on-one meetings.
Elutia (NASDAQ: ELUT) reported strong Q2 2025 results, driven by its flagship EluPro™ antibiotic bioenvelope. EluPro's Q2 revenue surged 49% sequentially, with BioEnvelope revenue reaching $3.5 million, up 33% year-over-year. The company has achieved significant market penetration with over 160 VAC-approved centers and strategic partnerships with Boston Scientific.
Total Q2 2025 revenue was $6.3 million, with gross margin improving to 48.8%. The company reported a net loss of $9.6 million. Elutia is advancing its pipeline with NXT-41, a next-generation drug-eluting biomatrix for breast reconstruction, targeting FDA clearance in 2H26. The company expects BioEnvelope sales to approach a $20 million annualized run rate by year-end.
Elutia (Nasdaq: ELUT), a drug-eluting biomatrix technologies company, has scheduled its second quarter 2025 financial results release for Thursday, August 14, 2025, after market close.
The company will host a conference call and webcast at 5:00 p.m. Eastern Time on the same day. Management will be available to discuss the results, with both domestic and international dial-in numbers provided for investor participation.
[]Elutia (Nasdaq: ELUT) announced that its Chief Scientific Officer, Dr. Michelle LeRoux Williams, has received the Medical Device Innovator Award from the Washington Business Journal. The recognition highlights her leadership in developing EluPro™, the first FDA-cleared antibiotic-eluting bioenvelope for cardiac implantable electronic devices (CIEDs).
EluPro, which received FDA clearance and launched commercially in January 2025, combines a regenerative biomatrix with antibiotics rifampin and minocycline. The technology addresses complications in CIEDs, with the market potential of over 600,000 annual CIED implants in the U.S., where complications occur in 5-7% of cases.
Elutia (NASDAQ: ELUT) announced new study results supporting the effectiveness of its EluPro BioEnvelope, an antibiotic-eluting device for cardiac implantable electronic devices (CIEDs). The study, published in the Journal of Functional Biomaterials, demonstrated that EluPro's biomatrix effectively controls inflammation and supports vascularization.
Research from the Cumming School of Medicine showed that EluPro stimulates early proangiogenic signals and reduces fibrosis over time. The study revealed significantly higher levels of growth and wound healing factors compared to controls (p0.001), with long-term animal studies demonstrating improved blood vessel formation and reduced inflammation over a .
EluPro, which received FDA clearance and was commercially launched in the United States in January 2025, is the first and only antibiotic-eluting bioenvelope approved for use with CIEDs and neurostimulators.
Elutia (Nasdaq: ELUT) has received dual honors at the 2025 Medical Device Network Excellence Awards for Innovation and Product Launches, recognizing their EluPro™ Antibiotic-Eluting BioEnvelope technology. EluPro, launched in January 2025, is designed to protect cardiac implantable electronic devices and neurostimulators.
The product has shown strong commercial performance with 84% sequential sales growth in Q1 2025 and drove a 31% year-over-year increase in BioEnvelope sales. EluPro has secured approvals from 150 hospital value analysis committees and partnerships with seven major group purchasing organizations.
The technology addresses a significant market need, with over 600,000 CIEDs implanted annually in the U.S. and complications occurring in 5-7% of cases.